Loading
A phase 1/2 trial of Daraxonrasib, Elironrasib, Zoldonrasib in non-small-cell lung cancer and small-cell lung cancer, run by Revolution Medicines, Inc., now recruiting.
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT07397338 by Revolution Medicines, Inc., with 370 participants planned, started 2026-01-30 and due to reach its primary completion in 2029-05. Interventions recorded: Daraxonrasib, Elironrasib, Zoldonrasib, Ivonescimab, Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only). Conditions listed: Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC. No results are recorded here; the registry entry is the source.
Shares Elironrasib, Revolution Medicines, Daraxonrasib, Cisplatin.
Shares Zoldonrasib, Revolution Medicines, Cisplatin, Carboplatin.
Shares Elironrasib, Revolution Medicines, Daraxonrasib, Small-cell lung cancer.
Shares Ivonescimab, Bispecific antibodies, Carboplatin, Small-cell lung cancer.
Shares Zoldonrasib, Revolution Medicines, Daraxonrasib, Colorectal cancer.
Shares Zoldonrasib, Revolution Medicines, Daraxonrasib, Colorectal cancer.
Shares Ivonescimab, Bispecific antibodies, Carboplatin, Small-cell lung cancer.
Shares Revolution Medicines, Daraxonrasib, Small-cell lung cancer, Non-small-cell lung cancer.